Results 41 to 50 of about 3,649,731 (302)

A study on the pharmacokinetic bioequivalence of oral tablet formulations of riluzole among healthy volunteers utilizing HPLC-MS/MS

BMC Pharmacology and Toxicology
Introduction This randomized, open-label, two period, two treatment, fasting bioequivalence trial was conducted to demonstrate the bioequivalence between riluzole tablets manufactured by Jiangsu Enhua Pharmaceutical Co., Ltd.
Fei Yu, Rui Wang, Keli Wang, BoYang Lin, Xuan Zhou, Linghong Chen, Li Ma, Zheng Liao, Wanggang Zhang   +8 more
doaj   +1 more source

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer

Thoracic Cancer, 2023
Background The clinical characteristics and efficacy of human epidermal growth factor receptor‐2 (HER‐2)‐directed agents against HER2 mutations and HER2 fusions in breast cancer are obscure due to their low frequency. Methods We conducted a retrospective
Yuxin Mu, Yanchun Meng, Yiqun Du, Xiaojun Liu, Jian Zhang   +4 more
doaj   +1 more source

A shared latent space matrix factorisation method for recommending new trial evidence for systematic review updates

, 2018
Clinical trial registries can be used to monitor the production of trial evidence and signal when systematic reviews become out of date. However, this use has been limited to date due to the extensive manual review required to search for and screen ...
Bashir, Rabia, Bourgeois, Florence T., Coiera, Enrico, Dunn, Adam G., Orenstein, Liat, Surian, Didi   +5 more
core   +1 more source

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait, R. Al‐Saadi, A. Lopez‐Cortes, K. Dzhuma, M. Oostveen, J. Brok, S. Irtan, M. Weeks, J. Bate, S. Baker, R. Williams, M. Powis, D. Saunders, O. Olsen, T. Watson, S. Shelmerdine, S. Vaidya, L. Howell, C. Duncan, G. M. Vujanic, C. Stiller, G. P. Balchin, T. Chowdhury, K. Pritchard‐Jones   +23 more
wiley   +1 more source

Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states

Frontiers in Pharmacology, 2022
We conducted a phase I bioequivalence trial in healthy Chinese subjects in the fasting and postprandial states. The goal of this trial was to compare the pharmacokinetics and safety of the test preparation Cefaclor granule (Disha Pharmaceutical Group Co.,
Xinyao Qu, Qiaohuan Deng, Ying Li, Peng Li, Guangwen Liu, Yanli Wang, Zhengzhi Liu, Shuang Yu, Yang Cheng, Yannan Zhou, Jiahui Chen, Qing Ren, Zishu Yu, Zhengjie Su, Yicheng Zhao, Haimiao Yang   +15 more
doaj   +1 more source

A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers [PDF]

, 2017
Background: Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment.
Bjarnason, Georg A, Edeline, Julien, Escudier, Bernard, Faivre, Sandrine, Fartoux, Laetitia, Germann, Nathalie, Hirte, Hal, Jones, Robert, Mackay, Helen, Oza, Amit, Plummer, Ruth, Pouget, Jean-Christophe, Thistlethwaite, Fiona, Van Cutsem, Eric, Vergote, Ignace   +14 more
core   +1 more source

Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre): protocol for a multicentre, observational study followed by randomised controlled feasibility trial [PDF]

, 2020
Introduction Acute kidney injury (AKI) is a frequent complication after cardiac surgery with adverse short-term and long-term outcomes. Although prevention of AKI (PrevAKI) is strongly recommended, the optimal strategy is uncertain.
Arndt, Christian, Campos, Sara, Cegarra Sanmartin, Virginia, Di Prima, Ambra, Forni, Lui, García Álvarez, Mercedes, Gerss, Joachim, Grau Novellas, Neus, Grieshaber, Philippe, Haffner, Michael, Honore, Patrick M, Hoste, Eric A J, Irqsusi, Marc, Italiano, Stefano, Kellum, John, Kunst, Gudrun, Küllmar, Mira, L'acqua, Camilla, Massoth, Christina, Meersch, Melanie, Monaco, Fabrizio, Nair, Shrijit, Ostermann, Marlies, Thomson, Gary, Universitat Autònoma de Barcelona, Vandenberghe, Wim, Weiss, Raphael, Wempe, Carola, Wulf, Hinnerk, Zarbock, Alexander   +29 more
core   +2 more sources

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson, Ingrid Winship, Gary Hammerschlag, Laura Scardamaglia   +3 more
wiley   +1 more source

Establishing cost-effectiveness of genetic targeting of cancer therapies [PDF]

, 2011
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to ...
Harten, W.H. van, Joore, M.A., Retèl, Valesca P., Rutgers, E.J.Th.   +3 more
core   +1 more source

Bayesian clinical trial designs : Another option for trauma trials? [PDF]

, 2017
The UK-REBOA Trial is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project number 14/199/09). PP was supported by the MRC Network of Hubs for Trials Methodology Research (MR/L004933/1-R/N/P/B1).
Campbell, Marion K., Jansen, Jan O., MacLennan, Graeme, Pallmann, Philip, UK-REBOA Trial Investigators   +4 more
core   +2 more sources